Future work is necessary to determine whether the increased circulating FASN+ EVs in glioma patients are truly derived from the tumor cells and whether tumor-specific genetic alteration can be detected in EVs enriched by FASN immunoprecipitation or other techniques. This evidence concerns the gene FASN and central nervous system cancer.